Dr. Horvath is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4405 Weaver Pkwy
Warrenville, IL 60555Phone+1 630-352-5300Fax+1 630-352-5499
Summary
- Dr. Laura Horvath is a hematologist oncologist in El Cajon, CA. She received her medical degree from University of Toledo College of Medicine and has been in practice 19 years. She specializes in hematologic oncology and is experienced in hematologic oncology, and clinical research.
Education & Training
- University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1998 - 2001
- The University of Toledo College of MedicineClass of 1998
Certifications & Licensure
- IL State Medical License 2001 - 2026
Clinical Trials
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsEconomic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.Bhavik J. Pandya, Chi-Chang Chen, Bruno C. Medeiros, Catherine B McGuiness, Samuel Wilson
Journal of Managed Care & Specialty Pharmacy. 2020-04-13 - 442 citationsNivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, James N. Atkins, Mohammed M. Milhem
The Lancet. Oncology. 2018-03-01 - 39 citationsPredicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).M. A. Fuchs, Chen Yuan, Kaori Sato, Donna Niedzwiecki, Xing Ye
Annals of Oncology. 2017-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: